
## Sheliyan Raveenthiran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4147271/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 66.e1-66.e9.	1.6	20
2	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	6.4	18
3	Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT). Urologic Oncology: Seminars and Original Investigations, 2022, 40, 276.e1-276.e9.	1.6	8
4	Histological comparison between predictive value of preoperative 3â€T multiparametric MRI and <sup>68</sup> Gaâ€PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU International, 2021, 127, 71-79.	2.5	45
5	Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer and Prostatic Diseases, 2021, 24. 398-405.	3.9	2
6	Lichen sclerosus presenting as an isolated bulbar urethral stricture. Urology Case Reports, 2021, 39, 101794.	0.3	0
7	The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer and Prostatic Diseases, 2019, 22, 385-390.	3.9	39
8	The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2280-2288.	6.4	57
9	Risk of metastatic disease on <sup>68</sup> galliumâ€prostateâ€specific membrane antigen <scp>positron emission tomography</scp> / <scp>computed tomography</scp> scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU International, 2019, 124, 401-407.	2.5	80
10	Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with <sup>68</sup> Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Journal of Urology, 2019, 201, 815-820.	0.4	64